A B S T R A C T
Background. Although diabetic nephropathy (DN) is the most common cause for end-stage renal disease in western societies, its pathogenesis still remains largely unclear. A different gene pattern of diabetic and healthy kidney cells is one of the probable explanations. Numerous signalling pathways have emerged as important pathophysiological mechanisms for diabetesinduced renal injury. Methods. Glomerular cells, as podocytes or mesangial cells, are predominantly involved in the development of diabetic renal lesions. While many gene assays concerning DN are performed with whole kidney or renal cortex tissue, we isolated glomeruli from black and tan, brachyuric (BTBR) obese/obese (ob/ob) and wildtype mice at four different timepoints (4, 8, 16 and 24 weeks) and performed an mRNA microarray to identify differentially expressed genes (DEGs). In contrast to many other diabetic mouse models, these homozygous ob/ob leptindeficient mice develop not only a severe type 2 diabetes, but also diabetic kidney injury with all the clinical and especially histologic features defining human DN. By functional enrichment analysis we were able to investigate biological processes and pathways enriched by the DEGs at different disease stages. Altered expression of nine randomly selected genes was confirmed by quantitative polymerase chain reaction from glomerular RNA. Results. Ob/ob type 2 diabetic mice showed up-and downregulation of genes primarily involved in metabolic processes and pathways, including glucose, lipid, fatty acid, retinol and amino acid metabolism. Members of the CYP4A and ApoB family were found among the top abundant genes. But more interestingly, altered gene loci showed enrichment for processes and pathways linked to angioneogenesis, complement cascades, semaphorin pathways, oxidation and reduction processes and renin secretion.
Conclusion.
The gene profile of BTBR ob/ob type 2 diabetic mice we conducted in this study can help to identify new key players in molecular pathogenesis of diabetic kidney injury.
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I N T R O D U C T I O N
Due to increasing rates of patients with risk factors like overweight and obesity, the global prevalence of diabetes has nearly doubled since 1980 from 4.8% to 8.5% among adults [1] . Diabetic nephropathy (DN) as a major microvascular complication of diabetes is the primary cause for dialysis and endstage renal disease (ESRD) in developed countries, affecting 40% of all diabetic patients. The clinical features of diabetic kidney injury include microalbuminuria as an early sign that is often not detected, nephrotic kidney injury with oedema, hyperlipoproteinaemia and gross proteinuria, and finally result in complete loss of renal function over 2-3 years if not treated in an early stage. Histologically, DN is characterized by thickening of the glomerular basement membrane, mesangial matrix expansion and nodular sclerosis [2] . Despite the high prevalence and the extremely high costs for the global health systems of DN, the underlying mechanisms still remain unclear and therapeutic options are very limited. Many data suggest that glomerular cells are primarily involved in the development of DN [3] . To further elucidate the genetic profile of glomerular cells in the condition of DN, we performed an mRNA microarray using glomeruli from black and tan, brachyuric (BTBR) obese/obese (ob/ob) and wildtype (WT) mice. The mouse strain BTBR with the ob/ob leptin-deficiency mutation develops severe type 2 diabetes, insulin resistance and-most importantly for this model-a renal phenotype that closely resembles human DN. By 22 weeks diffuse mesangial sclerosis (focally approaching nodular glomerulosclerosis), focal arteriolar hyalinosis, mesangiolysis and mild interstitial fibrosis were present [4] . Thus, the aim of this study was to identify candidate genes and gene clusters that could contribute to the development of diabetic kidney injury in type 2 diabetic mice.
M A T E R I A L S A N D M E T H O D S
BTBR ob/ob mice as a model for diabetic nephropathy As mouse model for type 2 diabetes we used animals derived from the murine strain BTBR. BTBR WT mice inherently exhibited hyperinsulinaemia without developing a diabetic phenotype and served as control for BTBR ob/ob mice. The latter showed a homozygous deficiency in the leptin gene causing the absence of satiety and finally diabetes. For breeding heterozygous BTBR ob þ/À mice (BTBR.Cg-Lep ob /WiscJ, stock number: 004824) were purchased from The Jackson Laboratory (Sacramento, CA, USA). All mice were bred and housed under standard conditions with 12-h day-night cycle with free access to water and chow.
Glomeruli isolation and mRNA isolation
Glomeruli were isolated from 4-, 8-, 16-and 24-week-old female BTBR WT and BTBR ob/ob mice. We used three animals of each group (WT and ob/ob) at 4 weeks and four animals of each group (WT and ob/ob) at 8, 16 and 24 weeks. After cervical dislocation, kidneys were explanted and passed through a series of stainless steel sieves (150, 100, 70 and 50 mm). Glomeruli were collected, and the purity of the respective isolated glomeruli fractions was controlled by an Axiostar plus microscope (Zeiss, Jena, Germany).
Subsequent RNA extraction was conducted using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). RNA concentration and purity were determined by a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) prior to storage at -80 C.
GeneChip microarray assay
Sample preparation for microarray hybridization was carried out as described in the Affymetrix GeneChip WT PLUS Reagent Kit User Manual (Affymetrix, Inc., Santa Clara, CA, USA). In brief, 200 ng of total RNA was used to generate double-stranded cDNA. Subsequently synthesized cDNA of 15 mg was purified, and reverse-transcribed into sense-strand (ss) cDNA, where unnatural dUTP residues were incorporated.
Purified ss cDNA was fragmented using a combination of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1) followed by a terminal labelling with biotin. Of the fragmented and labelled ss cDNA, 5. 
Validation of DEGs by quantitative polymerase chain reaction
The expression levels of nine randomly selected differentially expressed genes (DEGs) were measured by quantitative polymerase chain reaction (qPCR) of glomerular RNA of 24-week-old WT and ob/ob mice with six animals per group. All samples were run in triplicates. Results were obtained as fold expression relative to the expression in the control group using the 2 ÀDDCt method. Normal distribution was calculated by the Shapiro-Wilk test. The primers used for the different genes are listed in Table 1 .
Data processing and differential expression analysis
Microarray data analysis. Summarized probe set signals in log2 scale were calculated by using the SST-RMA algorithm [5] with the Affymetrix GeneChip Expression Console v1.4 Software. CEL files were used to calculate average signal values, comparison fold changes and significance P-values using Transcriptome Analysis Console (TAC) software 4.0. Probe sets with a fold change >2.0-fold and an false discovery rate (FDR) P-value <0.05 were considered as significantly regulated.
Microarray data have been submitted to the Gene Expression Omnibus repository and are accessible through accession number GSE106841.
Functional enrichment analysis. For gene clustering and detection of enriched pathways related to the DEGs we used The Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/knowledge base/) 6.8 as a comprehensive set of functional annotation tools [6, 7] . 
In this study, we performed Gene Ontology (GO) biological process (BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses for the coding DEGs. A P < 0.05 after correction for multiple testing (BenjaminiHochberg) was set as a threshold.
All gene loci associated with nuclear proteins like histones among the DEGs were excluded from the functional enrichment analysis.
R E S U L T S

Identification of differential expressed genes
Using the TAC analysis software, we analysed DEGs at all four timepoints (4, 8, 16 and 24 weeks) between diabetic (BTBR ob/ob) and wildtype (BTBR WT) mice. All gene loci with a fold change <-2 or >2 and a significant FDR P-value (<0.05 after correction for multiple testing) have been defined differentially expressed and were used for further analysis. Supplementary data, Table S1 shows all significant DEGs in diabetic ob/ob mice compared with WT controls at the four different timepoints.
In total, 65 956 gene loci have been analysed at each timepoint, divided into multiple complex genes (15 332), pseudogenes (2758), non-coding (31 717), coding (11 264) and ribosomal (388) genes. The data set included 2728 small RNAs, 1729 precursor microRNAs and 16 tRNAs. Twenty-four genes have been detected as 'unassigned genes'. For further analysis, 'coding genes' were defined as all gene loci that either the software defined as 'coding' or that were 'multiple complex genes' and encoded a known protein. Figure 1 shows the number of DEGs at every timepoint and the extent of coding, non-coding, up-and downregulated genes.
Over the disease process the number of DEGs steadily increased. At 4 weeks, when proteinuria begins in ob/ob diabetic mice, only one gene (Akr1c18, aldo-keto reductase family 1, member C18) was differentially expressed. At 8 weeks, when glomerular hypertrophy and accumulation of mesangial matrix are present in the diabetic animals, 104, and at 16 weeks, when almost all histologic features of human DN can be found, 180 coding DEGs were detected. At the latest timepoint (24 weeks), 1044 of the identified DEGs were coding.
Over all four timepoints, among the top upregulated genes in diabetic mouse glomeruli, there are many genes that encode proteins and enzymes directly involved in glucose and lipid metabolism: Hmgcs2 (3-hydroxy-3-methylglutaryl-CoA-synthase2), responsible for ketogenesis in hyperglycaemia, several renal glucose transporters of the solute carrier (Slc) family and apolipoprotein B (ApoB) are among the top 15 upregulated genes at investigated timepoints. Interestingly, Cyp27b1 and Cyp24a1 as part of the superfamily of cytochrome P450, which catalyses the oxidation of organic substances, were also in the top 15 genes up-or downregulated in diabetic mouse kidneys. Figure 2 shows the 15 most up-and downregulated DEGs by fold-change at timepoints 8, 16 and 24 weeks.
Confirmation with qPCR
To validate the microarray results, we analysed the mRNA levels of nine randomly picked genes by using qPCR. Figure 3 shows the fold changes in mRNA expression in 24-week-old diabetic mice in comparison with the fold changes in the microarray. All examined gene loci downregulated in the microarray also showed lower expression on mRNA levels in polymerase chain reaction, whereas upregulated genes showed higher expression.
Validation through comparison with a human data set
For further validation, our data set was compared with a microarray data set of human diabetic glomeruli, accessible through GEO accession number GSE30122. In both data sets, around 70% (71.4% in humans, 68.9% in our study) of DEGs were downregulated. Of the 100 most abundant glomerular transcripts in the human data set [8] , 42 were also differentially expressed at 24 weeks in our study. As podocytes are key cells in the development of diabetic kidney injury, we looked at podocyte-specific transcripts. Within the top 100 regulated genes in humans, nine known gene loci that are specifically expressed in podocytes, are highly downregulated: Plce1, Ptgds, Nphs1, Nphs2, Synpo, Pla2r1, Wt1, Clic5 and Podxl [8] . Six of these nine transcripts also show significant downregulation at 24 weeks in our study. Figure 4 shows the fold changes of podocyte-specific transcripts in the two data sets. The high similarity in abundant genes serves as a quality control for our results.
Functional enrichment analysis
In total, from 4 to 24 weeks, up-and downregulated DEGs are involved in 50 different biological processes.
Looking at the single timepoints, there are no enriched BP terms at 4 weeks. At 8 weeks, chloride transport and excretion are the two BPs enriched by DEGs. At 16 weeks, DEGs enrich for 32 BP terms. The top 10 BP terms at that disease stage are mainly linked to lipid and glucose metabolic processes. At 24 weeks, 18 BP terms are significantly altered. Here, besides metabolic processes, angiogenesis, transmembrane transport, oxidation-reduction process, patterning of blood vessels, kidney development and glomerular visceral epithelial cell differentiation are among the 10 most significantly changed biological processes. Table 2 gives an overview of BP terms significantly enriched by DEGs over all timepoints, and at timepoints 8, 16 and 24 weeks.
Enriched canonical pathways at each timepoint could be identified by KEGG analyses and are shown in Table 3 , including involved DEGs.
While at 4 and 8 weeks, no pathways are significantly changed in diseased mice, at 16 weeks DEGs enrich for metabolic pathways, biosynthesis of antibiotics, peroxisome proliferator-activated receptor (PPAR) signalling pathway and retinol metabolism.
At 24 weeks, significantly changed pathways represented by DEGs are metabolic pathways, biosynthesis of unsaturated fatty acids, fatty acid metabolism, PPAR signalling pathway, renin secretion, biosynthesis of antibiotics, fatty acid degradation, fatty acid elongation, complement and coagulation cascades, and valine, leucine and isoleucine degradation.
As an example, Figure 5 shows which genes contribute to PPAR signalling pathway and which of these are differentially expressed at 24 weeks in diabetic ob/ob mice in our study.
D I S C U S S I O N
As most common cause for ESRD in industrial nations, there is an urgent need for further understanding the pathogenesis of DN in order to develop new therapeutic strategies. In this study, we performed microarray analysis of glomerular mRNA of BTBR ob/ob mice, serving as a reliable model for human DN.
Primarily, genes involved in metabolic pathways and metabolic biological processes could be shown to be differentially expressed in glomeruli of diabetic mice. These involve BP terms and pathways in glucose, lipid, fatty acid, retinol and amino acid metabolism. Diabetic glomeruli show increased expression of major enzymes of glycolysis, including pyruvate kinase (Pklr) and pyruvate dehydrogenase kinases (Pdk1 and Pdk4), as well as gluconeogenesis, like phosphoenolpyruvate carboxykinase 1 (Pck1). Furthermore, there is a significant enrichment in biological processes and pathways related to increased fatty acid metabolism (see Tables 2 and 3) . Interestingly, however, 8 of 10 DEGs enriching for 'biosynthesis of unsaturated fatty acids' show decreased expression levels (Table 3a) . Polyunsaturated fatty acids have positive effects on insulin sensitivity [9] . Our results indicate that proteins involved in synthesis of unsaturated fatty acids are downregulated in mice with impaired insulin sensitivity.
Increased levels of circulating branched-chain amino acids (BCAA) like valine, leucine and isoleucine are strongly associated with insulin resistance [10] . According to this finding, DEGs involved in 'valine, leucine and isoleucine degradation' are predominantly (9 out of 10) downregulated in diabetic mice (Table 3c ). All these metabolic changes in renal cells, increased glycolysis, increased fatty acid metabolism and decreased degradation of BCAA, have been reported in other murine models of DN [11] .
Several glucose transporters showed changes in their expression levels in different stages of the disease in this study. Among the 58 Slc transporters with altered expression levels (Table 4) , two need to be highlighted. Slc5a10, encoding SGLT5, an Na þ -dependent transporter of mannose, fructose, galactose and glucose, is among the top 10 upregulated genes in our study at 8, 16 and 24 weeks (Table 4; Figure 2 ). Not a lot is known about the function of this transporter, exclusively expressed in kidney cortex [12] , but a recent genome-wide association study could show association between different gene variants of Slc5a10 and levels of 1,5-anhydroglucitol, which is used as a biomarker for hyperglycaemic excursions [13] . Although its role in diabetic kidney injury needs to be confirmed, its exclusive renal Comparison of changes in gene expression of podocyte-specific transcripts in our data set (magenta) at 24 weeks and a human data set on diabetic glomeruli (blue, GSE30122). Genes marked with asterisk have not been differentially expressed in the mouse data set (fold change >À2).
Glomerular genes in diabetic nephropathy expression could make it an attractive future target. The second interesting transporter is Slc12a3, which is highly downregulated (fold change À3.34) in the early stage of DN at 8 weeks and included in 'chloride transport', one of two enriched processes in glomeruli of ob/ob mice at 8 weeks (Table 2b) . This gene encoding a thiazide-sensitive sodium chloride cotransporter is known to have strong association with susceptibility to diabetic kidney injury [14] . Our data suggest that changes of genes involved in chloride transport like Slc12a3 could contribute to development of DN in an early stage.
The PPAR signalling pathway was one of the most significantly enriched pathways in diabetic mice (see Table 3 ; Figure 5 ). An association of alterations in this pathway and 
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Glomerular genes in diabetic nephropathy development of DN has been shown in different animal models and in humans [15] . Members of the CYP450 superfamily are especially wellknown to play an important role in redox balance and management of oxidative stress [16, 17] . Oxidative stress is often discussed as a pathomechanism in the development of diabetic kidney injury [18] . Changes in expression of different CYP members could be shown in different diabetes models [19, 20] . Emphasizing the role of oxidative stress in DN pathogenesis, the BP term 'oxidation-reduction process' is significantly enriched at 16 and 24 weeks, but not at 8 weeks, suggesting that the production of reactive oxygen species (ROS) increases over time and shows its effects only at a later timepoint of the disease. In a murine model, apoptosis of podocytes, an important early feature of DN [21] , is driven by ROS production through upregulation of CYP4A [22] . Interestingly among many other genes within 'oxidation-reduction process' (Table 5a) , Ceruloplasmin (Cp), which is a pro-oxidant under severe oxidative stress, is significantly upregulated (fold change 2.53) at 16 weeks in diabetic kidneys (Supplementary data, Table S1 ). Serum Cp levels have recently been demonstrated to correlate with progression of diabetic kidney injury in humans [23] . DEGs involved in this biological process (Table 5a ) could serve as candidate targets to prevent ROS production and podocyte damage.
Apoptosis in podocytes in DN is also driven by upregulation of the renin-angiotensin-aldosterone system (RAAS) [24] . Supporting this fact, 'renin secretion' is enriched as a pathway in 24 weeks old ob/ob mice, which show all signs of human DN. Angiotensinogen (Agt) as important pre-agent in the RAAS cascade is highly upregulated from Week 8 to Week 24 ( Figure 2) . Overexpression of Agt in mice is associated with hypertension, albuminuria and, in a diabetic model, with increased cell apoptosis [25] . But more interestingly, the natriuretic peptide receptor 1 (Npr1), and two Guanylate cyclase genes (Gucy1a2, Gucy1b3) are significantly downregulated (Table 3a) within the 'renin secretion' pathway. Very recently, it was shown that the natriuretic peptide receptor guanylyl cyclase-A pathway was able to counteract aldosterone-induced glomerular injury by inhibiting the p38 map kinase (MAPK) [26] . In our data set, four members of the glutathione S-transferase (GST) gene family are downregulated: Gstt1, Gstm2, Gsta4 and Gstp1 (Supplementary data, Table S1 ). GSTP1 could be shown to inhibit the p38 MAPK [27] and loss of Gstt1 showed association with development of diabetic retinal injury [28] . Not much known about susceptibility for diabetic kidney injury, however. Our data suggest that increased p38 MAPK activity in DN is caused by downregulation of Guanylate cyclases and members of the GST gene family. DEGs upregulated in 'retinol metabolism' (enriched at Week 16) included Aldh1a1 and Aldh1a7 (Table 3b ). These two proteins, both part of the aldehyde dehydrogenase family, could be shown to be associated with insulin resistance and lipid disorders [29] . Vitamin A and retinol metabolism could have an important impact on development of diabetic kidney injury.
Furthermore, a lot of dysregulated DEGs identified in our assay, are involved in BP terms linked to new vessel formation and angiogenesis.
In diabetic retinopathy, abnormal angiogenesis is wellaccepted as main pathogenetic factor. Diabetic kidney injury as well is associated with abnormal angioneogenesis and altered vascular growth factor signalling [30] . Confirming these results, two BP terms closely linked to new vessel formation are among the highly enriched BP at 24 weeks: 'angiogenesis' and 'patterning of blood vessels'. Table 5b shows DEGs involved in these BP terms. Among them, Angptl4 (Angiopoietin-like 4) can be found as one of the top 10 upregulated transcripts at 16 and 24 weeks (Figure 2 ) and its upregulation could be confirmed by qPCR (Figure 3 ). This secreted glycoprotein, belonging to the superfamily of angiogenic-regulating proteins, is a PPAR target and highly expressed in liver and adipose tissue [31] . As an inhibitor of lipoprotein lipase (Lpl, significantly downregulated As an example for enriched KEGG pathways, this figure shows the involved genes of the PPAR signalling pathway. Genes identified as differentially expressed at timepoint 24 weeks in our assay are marked in colour. Red means up-and green downregulated. The stronger the colour, the higher the fold change of this transcript. Gene loci shown in white have not been differentially expressed in our data set. Over all four timepoints, 58 different Slc members were differentially expressed. Slc5a10, highlighted in bold, is highly upregulated at 8, 16 and 24 weeks. in this study at 8, 16 and 24 weeks), it is strongly associated with hypertriglyceridaemia [31] . More recently, it could be shown that ANGPTL4 is expressed in glomeruli and that its expression is highly upregulated in podocytes of human and animal models of minimal change disease, a typical nephrotic disease caused by podocyte injury [31] . Podocyte-specific overexpression of ANGPTL4 in rats leads to nephrotic-range proteinuria, while Angptl4 knock-out mice show significantly lower levels of proteinuria [32] . Meanwhile, increased secretion of ANGPTL4 by podocytes has also been shown in a rat model of streptozocin-induced DN [32] . In the same rat model, RAAS inhibition, which is a common therapeutic approach in DN, by benazepril hydrochloride led to decrease in ANGPTL4 expression [33] . New therapeutic approaches aiming specifically at Angptl4 have already been described in animal models and could successfully reduce proteinuria [34] . Although these intriguing data need to be confirmed in human DN, our results emphasize the impact of angioneogenesis and upregulation of Angptl4 as an important feature of late DN and a promising future therapeutic target. Besides several well-known genes closely linked to renal function, like Ace [35] , Ren1 [35, 36] and Umod [37] , two very interesting genes show significantly altered expression at a late disease stage: nephrin (Nphs1) and neuropilin 1 (Nrp1). Mutations in the Nphs1 gene locus are associated with congenital nephrotic syndrome and early-onset CKD [38, 39] . As a major component of the slit membrane, alterations in this podocyte gene could also play a role in development of a nephrotic kidney disease such as DN. NRP1, originally reported as an adhesion receptor in the nervous system, also seems to play an important role in endothelial cells via its binding to vascular endothelial growth factor A (VEGF-A) [40] and is highly downregulated at 24 weeks in diabetic glomeruli. In the kidney, Nrp1 is mainly expressed by differentiated podocytes [41] and is implicated in podocyte adhesion and migration [42] . In differentiated podocytes cultured in the presence of glycated-BSA, Nrp1 was significantly downregulated [41] . Furthermore, a reduced NRP1 protein expression could be demonstrated in the glomeruli of diabetic db/db mice [43] and in kidney biopsies from patients with DN [41] .
Nrp1 also plays an important role in the field of axon guidance, a pathway that is little studied in DN. The so-called semaphorins are known ligands of NRP1 and are expressed in glomerular podocytes [44] . Three members of this group, Sema3g, Sema5a and Sema5e, are significantly dysregulated at 24 weeks. Different data suggest a critical function of semaphorins in vascular morphogenesis and podocyte-endothelial crosstalk [44] . A large transcriptional data set on human diabetic glomeruli also shows two of these three dysregulated semaphorins (Sema5a and Sema3g) among the top 100 dysregulated transcripts and 'semaphorin signaling in neurons' as one of the enriched pathways [8] . Taken together, results of our microarray data show that alterations of genes involved in axon guidance, like Nrp1 and members of the semaphorin family, seem to play an important role in the late stage of DN.
Finally, DEGs in diabetic glomeruli at 24 weeks show an enrichment for 'complement and coagulation cascades' (Table 3 ). In DN, the belief is that glycation of complementregulatory proteins leads to their dysfunction and subsequently to an overactive complement response. Elevated levels of different complement molecules, including C3, have been shown in DN in mice and humans [8, 45] .
An upregulation of C3 can be confirmed in our data set at 16 and 24 weeks. Although different approaches to therapeutically target the complement system are successfully used in other disease entities, only few experimental studies have tried these substances in the context of DN. Our data support the major contribution of this complex system to the development of DN and suggest emphasizing attempts to block different components in order to stop disease progression.
C O N C L U S I O N
The microarray data of glomeruli from ob/ob diabetic mice show an alteration in one gene locus at 4 weeks of age, increasing to 1044 DEGs at 24 weeks. Up-and downregulated DEGs were enriched for mainly metabolic biological processes and pathways, including glycolysis, gluconeogenesis, fatty acid and lipid metabolism, amino acid metabolism, retinol and PPAR signalling. Besides that, our results indicate that genes involved in angioneogenesis, complement and coagulation cascades, semaphorin pathways and axon guidance, oxidation and reduction processes, and renin secretion play an important role in the molecular pathogenesis of DN. These findings can help to identify new candidate genes and gene clusters for the development of diabetic kidney injury.
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